Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SPN-821

Small molecule · Activator of mTORC1 · developed by Supernus Pharmaceuticals

Phase 2 Most advanced trial
SUPN Developer
1 Registered trials

What is SPN-821?

SPN-821 is an orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling. It is being studied in major depressive disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
mTORC1
Mechanism
Activator of mTORC1
Pathways
mTORC1 signaling
Therapy area
Psychiatry
Developer
Supernus Pharmaceuticals, Inc. (SUPN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07226661 Phase 2 Major Depressive Disorder (MDD) Recruiting SUPN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Major Depressive Disorder (MDD)

More from Supernus Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SUPN page.

Follow SUPN, the company behind SPN-821

See SUPN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SUPN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.